

Attorney Docket No. UNI.26

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	QI JIA	}
SERIAL NO.:	10/817,330	
FILED:	APRIL 02, 2004	
TITLE:	FORMULATION OF DUAL CYCLOXYGENASE (COX) AND LIPOXYGENASE (LOX) INHIBITORS FOR MAMMAL SKIN CARE	

EXAMINER:
ART UNIT: 1614
CONFIRMATION NO.: 1136

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

4TH INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the publication listed on the attached Form PTO-1449, a copy of the required document is enclosed, which may be material to examination of the above identified application. In accordance with 37 CFR § 1.98(a)(3)(i) the relevance of CN 1043406 C is set forth in its abstract, the English translation of which is provided.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:

- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

37 CFR 1.8
CERTIFICATE OF MAILING


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 25, 2005.

Signature: Denise S. Magee
Name: Denise S. Magee

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: May 25, 2005


Rosemary Kellogg, #39,726
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
303-268-0066 Telephone
303-268-0065 Facsimile

cc: Thomas J. Hoolihan

Qi Jia

S:\CLIENTFOLDERS\UNIGEN PHARMACEUTICALS\UNI23\UTILITY\SUPP IDS 03.DOC

Q1P
FORM PTO-1449 U.S. DEPARTMENT OF
COMMERCE PATENT
AND TRADEMARK
OFFICE

MAY 31 2005
List of Information Cited by Applicant
Page 1 of 1

ATTY. DOCKET NO. UNI.26	SERIAL NO. 10/817,330
APPLICANT QI JIA	
FILING DATE APRIL 02, 2004	GROUP 1614

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AR	CN 1043406 C	05-19-1999	CHINA (<i>Abstract Only</i>)			
	AS						
	AT						
	AU						
	AV						
	AW						
	AX						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AY	
AZ	
AAA	
AAB	
AAC	
AAD	

EXAMINER DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.